Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levoleucovorin

FDA-approved product (powder, intravenous), marketed as Khapzory, Fusilev, Levoleucovorin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levoleucovorin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Osteosarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levoleucovorin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levoleucovorin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

    NCT07616362 · start 2026-06

    Registered record
    Registry ID
    NCT07616362
    Conditions
    Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Interventions
    Nab paclitaxel / gemcitabine; mFOLFIRINOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06
    Completion
    2031-04
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBorderline Resectable Pancreatic Ductal Adenocarcinoma
    InterventionNab paclitaxel / gemcitabine; mFOLFIRINOX
    PhasePhase 2
    Registry statusNot yet recruiting

  • Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

    NCT07469956 · start 2026-03-31

    Registered record
    Registry ID
    NCT07469956
    Conditions
    Pancreatic Cancer Resectable
    Interventions
    Surufatinib; Toripalimab; mFOLFIRINOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-31
    Completion
    2029-01-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer Resectable
    InterventionSurufatinib; Toripalimab; mFOLFIRINOX
    PhasePhase 2
    Registry statusNot yet recruiting

  • Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

    NCT05296005 · start 2025-12-31

    Registered record
    Registry ID
    NCT05296005
    Conditions
    Clinical Stage I Gastric Cancer AJCC v8; Clinical Stage II Gastric Cancer AJCC v8; Clinical Stage IIA Gastric Cancer AJCC v8; Clinical Stage IIB Gastric Cancer AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Gastric Adenocarcinoma; Pathologic Stage IB Gastric Cancer AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Gastric Cancer AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastric Cancer AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastric Cancer AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage III Gastroesophageal Junction Adeno
    Interventions
    Capecitabine; Docetaxel; Fluorouracil; Leucovorin; Oxaliplatin; Radiation Therapy; Surgical Procedure
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2025-12-31
    Completion
    2025-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage I Gastric Cancer AJCC v8; Clinical Stage II Gastric Cancer AJCC v8; Clinical Stage IIA Gastric Cancer AJCC v8; Clinical Stage IIB Gastric Cancer AJCC v8 +15 more
    InterventionCapecitabine; Docetaxel; Fluorouracil; Leucovorin +3 more
    PhasePhase 1
    Registry statusWithdrawn

  • Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

    NCT07061080 · start 2025-12-18

    Registered record
    Registry ID
    NCT07061080
    Conditions
    Advanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin
    Interventions
    Tarlatamab; standard of care second-line chemotherapy (FOLFIRI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2025-12-18
    Completion
    2026-09-03
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin
    InterventionTarlatamab; standard of care second-line chemotherapy (FOLFIRI)
    PhasePhase 2
    Registry statusTerminated

  • Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

    NCT06700603 · start 2024-11-20

    Registered record
    Registry ID
    NCT06700603
    Conditions
    Pancreatic Cancer
    Interventions
    Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-11-20
    Completion
    2026-12-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionIrinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    NCT06662786 · start 2024-10-18

    Registered record
    Registry ID
    NCT06662786
    Conditions
    Colorectal Neoplasms
    Interventions
    Amivantamab; Cetuximab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Oxaliplatin; Irinotecan Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-10-18
    Completion
    2032-01-20
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    InterventionAmivantamab; Cetuximab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin +2 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

    NCT06447662 · start 2024-06-27

    Registered record
    Registry ID
    NCT06447662
    Conditions
    Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
    Interventions
    PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin; Sasanlimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2024-06-27
    Completion
    2026-10-09
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung
    InterventionPF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab +10 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma

    NCT06278545 · start 2024-02-16

    Registered record
    Registry ID
    NCT06278545
    Conditions
    Locally Advanced or Metastatic Small Bowel Adenocarcinoma
    Interventions
    modified FOLFORINOX; Modified FOLFOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-02-16
    Completion
    2029-02
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced or Metastatic Small Bowel Adenocarcinoma
    Interventionmodified FOLFORINOX; Modified FOLFOX
    PhasePhase 2
    Registry statusRecruiting

  • Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

    NCT06197438 · start 2024-01-01

    Registered record
    Registry ID
    NCT06197438
    Conditions
    Gastric Cancer
    Interventions
    Tislelizumab; Oxaliplatin; Levo-Leucovorin; 5-fluorouracil; Irinotecan Hydrochloride; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-01-01
    Completion
    2025-04-01
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionTislelizumab; Oxaliplatin; Levo-Leucovorin; 5-fluorouracil +2 more
    PhasePhase 2
    Registry statusUnknown

  • The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.

    NCT06068023 · start 2023-07-01

    Registered record
    Registry ID
    NCT06068023
    Conditions
    Ampullary Adenocarcinoma
    Interventions
    Folfirinox; Capox
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2029-07-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmpullary Adenocarcinoma
    InterventionFolfirinox; Capox
    PhaseNot recorded
    Registry statusRecruiting

  • LEAC-102 for Advanced Colorectal Cancer

    NCT02826837 · start 2022-09-01

    Registered record
    Registry ID
    NCT02826837
    Conditions
    Advanced Colorectal Cancer
    Interventions
    LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-09-01
    Completion
    2024-02-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Colorectal Cancer
    InterventionLEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

    NCT05797883 · start 2022-08-01

    Registered record
    Registry ID
    NCT05797883
    Conditions
    Unresectable or Metastatic Colorectal Cancer
    Interventions
    FOLFOX/FOLFIRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-08-01
    Completion
    2024-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnresectable or Metastatic Colorectal Cancer
    InterventionFOLFOX/FOLFIRI
    PhasePhase 2
    Registry statusUnknown

  • A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

    NCT05383352 · start 2022-05-30

    Registered record
    Registry ID
    NCT05383352
    Conditions
    Metastatic Pancreatic Adenocarcinoma
    Interventions
    Irinotecan liposome injection; Irinotecan liposome injection; Irinotecan liposome injection; Irinotecan liposome injection; Folinic Acid; 5-Fluorouracil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-05-30
    Completion
    2025-04-15
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Adenocarcinoma
    InterventionIrinotecan liposome injection; Irinotecan liposome injection; Irinotecan liposome injection; Irinotecan liposome injection +2 more
    PhasePhase 1
    Registry statusCompleted

  • FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

    NCT05018182 · start 2021-08-02

    Registered record
    Registry ID
    NCT05018182
    Conditions
    High-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen
    Interventions
    Oxaliplatin; Irinotecan; Folinic Acid; 5FU; Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-08-02
    Completion
    2022-08-02
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh-risk Locally Advanced Colorectal Cancer; Neoadjuvant Chemotherapy; FOLFOXIRI Regimen
    InterventionOxaliplatin; Irinotecan; Folinic Acid; 5FU +1 more
    PhasePhase 2
    Registry statusUnknown

  • NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

    NCT04539808 · start 2021-05-27

    Registered record
    Registry ID
    NCT04539808
    Conditions
    Pancreatic Adenocarcinoma; Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8; Stage I Pancreatic Cancer American Joint Committee on Cancer v8; Stage III Pancreatic Cancer American Joint Committee on Cancer v8; Stage IV Pancreatic Cancer American Joint Committee on Cancer v8
    Interventions
    Capecitabine; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium; Losartan Potassium; Oxaliplatin; Radiation Therapy; Resection; Diagnostic Imaging; Biospecimen Collection; Gemcitabine; Nab paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-05-27
    Completion
    2027-01-05
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma; Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8; Stage I Pancreatic Cancer American Joint Committee on Cancer v8; Stage III Pancreatic Cancer American Joint Committee on Cancer v8 +1 more
    InterventionCapecitabine; Fluorouracil; Irinotecan Hydrochloride; Leucovorin Calcium +8 more
    PhasePhase 2
    Registry statusActive not recruiting